G1 Therapeutics, Inc. (GTHX) Social Stream



G1 Therapeutics, Inc. (GTHX): $20.99

0.04 (+0.19%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GTHX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 485

in industry

Featured Post From StockTwits About GTHX

$GTHX Long GTHX and holding for $100+....why?

Its all about market uptake and execution and they have the playbook to success. Patients/oncologists need/want the treatment...myelosuppression is an unmet market. Bailey ran US ops for Glaxo and has almost 30 years of pharma experience, the CCO successfully rolled out Tafamidis for $PFE to the tune of over $1b in annual sales. They have the experience and the playbook to succeed. They partnered with Boehringer Ingelheim for 3 years to crank up the Cosela sales and establish the market. They will execute and succeed. Long and will add the dips.!!!!
tdorsey, published June 14, 2021

What Else are GTHX Traders Talking About?


Other tickers frequently mentioned alongside GTHX is PFE.

Other Notable StockTweets About GTHX


$GTHX Why is this a high conviction bio investment?

Its all about market uptake and execution and they have the playbook to success. Patients/oncologists need/want the treatment...myelosuppression is an unmet market. Bailey ran US ops for Glaxo and has almost 30 years of pharma experience, the CCO successfully rolled out Tafamidis for $PFE to the tune of over $1b in annual sales. They have the experience and the playbook to succeed. They partnered with Boehringer Ingelheim for 3 years to crank up the Cosela sales and establish the market. They will execute and succeed. KNOW WHAT YOU OWN! GLTA.

Long and strong....buy/add the dips.!!!!

tdorsey, published June 11, 2021

$GTHX Not a lot of activity here, as GTHX isn't a company to draw much attention. However, don't be fooled, this is an exiting time for longs. Q1 gave us a pleasant suprise regarding quick uptake in Cosela and I see them hitting it out of the park again in Q2. This makes the company basically derisked. Everything else will be absolute beautiful suprises. First up is Rinto data at ASCO and later down the year we will have readout for Cosela's efficacy in two more cancers. When these things work, and for Cosela I think the chances are higher because it has already shown efficacy and safety, there is nothing stopping us from marching to $100. Jack will lead the way.

BobbyBoljaar, published May 28, 2021

$GTHX

The rintodestrant results are early and trending towards what the company hoped for, a clinical benefit response at 24 weeks (CBR24) of 60%-65%. For those unfamiliar with CBR, it equals complete response (CR) + partial response (PR) + stable disease (SD). At the time of reporting, the median treatment duration was 3 months (1.5 - 4.6), so only 12 weeks. The data is young and needs to mature. But the CBR is 73%, 2 (5%) confirmed PR’s and 27 (68%) with SD. There are still 28 patients (70%) on treatment. The safety profile is excellent as expected, with adverse events (AEs) attributed to rintodestrant at only 8%, all non-serious, and grade 2.

Hopefully, the company will provide a little more color on these data, and once it matures, give an update. Regardless, the early results are impressive and should attract interest from pharma that might want to acquire the rights to rintodestrant.

TheGiantKiller, published May 20, 2021

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7371 seconds.